Therapy and prevention of cryptosporidiosis in animals

Veterinary Parasitology

Volumn 188, Issue 3-4, 2012, Pages 203-214

  Shahiduzzaman, Md ^a   Daugschies, Arwid ^b  

^a BANGLADESH AGRICULTURAL UNIVERSITY   (Bangladesh)

^b UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Animal; Cryptosporidium; Prevention; Therapy

Indexed keywords

ACTIVATED CARBON; ANTIPROTOZOAL AGENT; AURINTRICARBOXYLIC ACID; AZITHROMYCIN; BENZIMIDAZOLE DERIVATIVE; BOBEL 24 (2,4,6 TRIOODOPHENYL); BROXYQUINOLINE; CLOXACILLIN; CLOXIQUINE; CURCUMIN; DECOQUINATE; DEHYDROCHOLIC ACID; DISINFECTANT AGENT; ENROFLOXACIN; HALOFUGINONE; LASALOCID; MILTEFOSINE; NITAZOXANIDE; PAROMOMYCIN; RANALEXIN; SINEFUNGIN; SODIUM SELENITE; TIZOXANIDE; TYLOSIN; UNCLASSIFIED DRUG;

ANTIPROTOZOAL ACTIVITY; BOVIDS; CAT; CHICKEN; CRYPTOSPORIDIOSIS; DOG; DRUG ABSORPTION; DRUG EFFICACY; DRUG MECHANISM; HORSE; HUMAN; IMMUNIZATION; IN VITRO STUDY; IN VIVO STUDY; INFECTION CONTROL; INFECTION PREVENTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; REPTILE; REVIEW; SWINE; WILDLIFE;

ANIMALS; ANTIPROTOZOAL AGENTS; CRYPTOSPORIDIOSIS; CRYPTOSPORIDIUM; DRUG RESISTANCE; HUMANS; OOCYSTS;

ANIMALIA; CRYPTOSPORIDIUM;

EID: 84864550372     PISSN: 03044017     EISSN: 18732550     Source Type: Journal    
DOI: 10.1016/j.vetpar.2012.03.052     Document Type: Review

References (146)

1. Abubakar I., Aliyu S.H., Arumugam C., Usman N.K., Hunter P.R. Treatment of cryptosporidiosis in immunocompromised individuals: systematic review and meta-analysis. Br. J. Clin. Pharmacol. 2007, 63:387-393.
2. Akiyama T., Ishida J., Nakagawa S., Ogawara H., Watanabe S., Itoh N., Shibuya M., Fukami Y. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J. Biol. Chem. 1987, 262:5592-5595.
3. Alves M., Matos O., Fonseca I., Delgado E., Lourenco A., Antunes F. Multilocus genotyping of Cryptosporidium isolates from human HIV-infected and animal hosts. J. Eukaryot. Microbiol. Suppl. 2001, 17S-18S.
4. Anderson B.C. Moist heat inactivation of Cryptosporidium sp. Am. J. Public Health 1985, 75:1433.
5. Angus K.W., Sherwood D., Hutchison G., Campbell I. Evaluation of the effect of two aldehyde-based disinfectants on the infectivity of faecal cryptosporidia for mice. Res. Vet. Sci. 1982, 33:379-381.
6. Armson A., Meloni B.P., Reynoldson J.A., Thompson R.C.A. Assessment of drugs against Cryptosporidium parvum using a simple in vitro screening method. FEMS Microbiol. Lett. 1999, 178:227-233.
7. Artz J.D., Dunford J.E., Arrowood M.J., Dong A., Chruszcz M., Kavanagh K.L., Minor W., Russell R.G., Ebetino F.H., Oppermann U., Hui R. Targeting a uniquely nonspecific prenyl synthase with bisphosphonates to combat cryptosporidiosis. Chem. Biol. 2008, 15:1296-1306.
8. Baishanbo A., Gargala G., Duclos C., Francois A., Rossignol J.F., Ballet J.J., Favennec L. Efficacy of nitazoxanide and paromomycin in biliary tract cryptosporidiosis in an immunosuppressed gerbil model. J. Antimicrob. Chemother. 2006, 57:353-355.
9. Baldursson S., Karanis P. Waterborne transmission of protozoan parasites: review of worldwide outbreaks-an update 2004-2010. Water Res. 2011, 45:6603-6614.
10. Barr S.C., Jamrosz G.F., Hornbuckle W.E., Bowman D.D., Fayer R. Use of paromomycin for treatment of cryptosporidiosis in a cat. J. Am. Vet. Med. Assoc. 1994, 205:1742-1743.
11. Blagburn B.L., Soave R. Prophlaxis and chemotherapy: human and animal. Cryptosporidium and Cryptosporidiosis 1997, 11-128. CRC Press, Boca Raton, FL. R. Fayer (Ed.).
12. Blagburn B.L., Drain K.L., Land T.M., Kinard R.G., Moore P.H., Lindsay D.S., Patrick D.A., Boykin D.W., Tidwell R.R. Comparative efficacy evaluation of dicationic carbazole compounds, nitazoxanide, and paromomycin against Cryptosporidium parvum infections in a neonatal mouse model. Antimicrob. Agents Chemother. 1998, 42:2877-2882.
13. Blewett D.A. Quantitative techniques in Cryptosporidium research. Cryptosporidiosis: Proceedings of the First International Workshop 1988, 107. K.W. Angus, D.A. Blewett (Eds.).
14. Brasseur P., Lemeteil D., Ballet J.J. Curative and preventive anticryptosporidium activities of sinefungin in an immunosuppressed adult rat model. Antimicrob. Agents Chemother. 1993, 37:889-892.
15. Brasseur P., Favennec L., Lemeteil D., Roussel F., Ballet J.J. An immunosuppressed rat model for evaluation of anti-Cryptosporidium activity of sinefungin. Folia Parasitol. (Praha) 1994, 41:13-16.
16. Brockmann S.O., Jakobi V., Dreweck C., Wagner-Wiening C., Hagen R.M., Kimmig P., Petry F. Serological and epidemiological analysis of an outbreak of gastroenteritis among Military recruits in Germany caused by Cryptosporidium parvum. Infection 2008, 36:450-457.
17. Caccio S.M. Molecular epidemiology of human cryptosporidiosis. Parassitologia 2005, 47:185-192.
18. Cai X., Woods K.M., Upton S.J., Zhu G. Application of quantitative real-time reverse transcription-PCR in assessing drug efficacy against the intracellular pathogen Cryptosporidium parvum in vitro. Antimicrob. Agents Chemother. 2005, 49:4437-4442.
19. Campbell I., Tzipori S., Hutchison G., Angus K.W. Effect of disinfectants on survival of Cryptosporidium oocysts. Vet. Rec. 1982, 111:414-415.
20. Carmel B.P., Groves V. Chronic cryptosporidiosis in Australian elapid snakes: control of an outbreak in a captive colony. Aust. Vet. J. 1993, 70:293-295.
21. Castro-Hermida J.A., Pors I., Ares-Mazas E., Chartier C. In vitro activity on Cryptosporidium parvum oocyst of different drugs with recognised anticryptosporidial efficacy. Rev. Med. Vet. 2004, 155:453-456.
22. Castro-Hermida J.A., Pors I., Méndez-Hermida F., Ares-Mazás E., Chartier C. Evaluation of two commercial disinfectants on the viability and infectivity of Cryptosporidium parvum oocysts. Vet. J. 2006, 171:340-345.
23. Causape A.C., Sanchez-Acedo C., Quilez J., del Cacho E., Viu M. Efficacy of alofuginone lactate against natural Cryptosporidium parvum infections in lambs. Res. Rev. Parasitol. 1999, 59:41-46.
24. Chartier C., Mallereau M.P., Naciri M. Prophylaxis using paro-momycin of natural cryptosporidial infection in neonatal kids. Prev. Vet. Med. 1996, 25:357-361.
25. Chartier C., Mallereau M.P., Lenfant D. Halofuginone lactate in the control of cryptosporidiosis in neonate kids. Rev. Med. Vet. 1999, 150:341-346.
26. Chunge C.N., Owate J., Pamba H.O., Domo L. Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate. T. Roy. Soc. Trop. Med. H 1990, 84:221-225.
27. Collick A.S., Fogarty E.A., Zieglar P.E., Walter M.T., Bowman D.D., Steenhuis T.S. Survival of Cryptosporidium parvum oocysts in calf housing facilities in the New York City watersheds. J. Environ. Qual. 2006, 35:680-687.
28. Cranfield M.R., Graczyk T.K., Wright K., Frye F.L., Raphael B. Cryptosporidiosis. Bull. Assoc. Reptl. Amphib. Vet. 1999, 9:15-21.
29. Dale K., Kirk M., Sinclair M., Hall R., Leder K. Reported waterborne outbreaks of gastrointestinal disease in Australia are predominantly associated with recreational exposure. Aust. Nz. J. Publ. Heal. 2010, 34:527-530.
30. De Graaf D.C., Vanopdenbosch E., Ortega-Mora L.M., Abbassi H., Peeters J.E. A reviewof the importance of cryptosporidiosis in farm animals. Intern. J. Parasitol. 1999, 29:1269-1287.
31. Delafosse A., Castro-Hermida J.A., Baudry C., Ares-Mazas E., Chartier C. Herd-level risk factors for Cryptosporidium infection in dairy-goat kids in western France. Prev. Vet. Med. 2006, 77:109-121.
32. Di Giovanni G.D., LeChevallier M.W. Quantitative-PCR assessment of Cryptosporidium parvum cell culture infection. Appl. Environ. Microbiol. 2005, 71:1495-1500.
33. Downey A.S., Chong C.R., Graczyk T.K., Sullivan D.J. Efficacy of pyrvinium pamoate against Cryptosporidium parvum infection in vitro and in a neonatal mouse model. Antimicrob. Agents Chemother. 2008, 52:3106-3112.
34. Eckert E. Studien zur Vitalitätsabschätzung von Cryptosporidium parvum 2001, Diss. Tierärztliche Hochschule, Hannover.
35. Elitok B., Özgül M.E., Hüseyin P. Efficacy of azithromycin dihydrate in treatment of cryptosporidiosis in naturally infected dairy calves. J. Vet. Intern. Med. 2005, 19:590-593.
36. Egraz-Bernard M., Favennec L., Agnamey P., Ballet J.J., Brasseur P. Inhibition of complete development of Cryptosporidium parvum in Caco-2 cells. Eur. J. Clin. Microbiol. Infect. Dis. 1996, 15:897-900.
37. Ethelberg S., Lisby M., Vestergaard L.S., Enemark H.L., Olsen K.E.P., Stensvold C.R., Nielsen H.V., Porsbo L.J., Plesner A.M., Mølbak K. A foodborne outbreak of Cryptosporidium hominis infection. Epidemiol. Infect. 2009, 137:348-356.
38. Euzeby J., Prom Tep S., Rossignol J.F. Study of the anthelminthic properties of nitazoxanide in dog, cat and sheep. Rev. Med. Vet. 1980, 131:687-696.
39. Fayer R., Ellis W. Paromomycin is effective as prophylaxis for cryptosporidiosis in dairy calves. J. Parasitol. 1993, 79:771-774.
40. Fayer R. Effect of sodium hypochlorite exposure on infectivity of Cryptosporidium parvum oocysts for neonatal BALB/c mice. Appl. Environ. Microbiol. 1995, 61:844-846.
41. Fayer R., Dubey J.P., Lindsay D.S. Zoonotic protozoa: from land to sea. Trends Parasitol. 2004, 20:531-536.
42. Fontaine M., Guillot E. Development of a TaqMan quantitative PCR assay specific for Cryptosporidium parvum. FEMS Microbiol. Lett. 2002, 214:13-17.
43. Fox L.M., Saravolatz L.D. Nitazoxanide: a new thiazolide antiparasitic agent. Rev. Anti Infect. Agents 2005, 40:1173-1180.
44. Fritzler J.M., Zhu G. Novel anti-Cryptosporidium activity of known drugs identified by high-throughput screening against parasite fatty acyl-CoA binding protein (ACBP). J. Antimicrob. Chemother. 2012, 67:609-617.
45. Funk R.S. Implications of cryptosporidiosis in emerald tree boas (Corralus caninus). Proceedings of 11th International Herpetological Symposium 1987, 139-144.
46. Gargala G., Delaunay A., Favennec L., Brasseur P., Ballet J.J. Enzyme immunoassay detection of Cryptosporidium parvum inhibition by sinefungin in sporozoite infected HCT-8 enterocytic cells. Int. J. Parasitol. 1999, 29:703-709.
47. Gargala G., Delaunay A., Li X., Brasseur P., Favennec L., Ballet J.J. Efficacy of nitazoxanide, tizoxanide and tizoxanide glucuronide against Cryptosporidium parvum development in sporozoite-infected HCT-8 enterocytic cells. J. Antimicrob. Chemother. 2000, 46:57-60.
48. Gargala G., Baishanbo A., Favennec L., François A., Ballet J.J., Rossignol J.F. Inhibitory activities of epidermal growth factor receptor tyrosine kinase-targeted dihydroxyisoflavone and trihydroxydeoxybenzoin derivatives on Sarcocystis neurona, Neospora caninum, and Cryptosporidium parvum development. Antimicrob. Agents Chemother. 2005, 49:4628-4634.
49. Gargala G. Drug treatment and novel drug target against Cryptosporidium. Parasite 2008, 15:275-281.
50. Gargala G., Le Goff L., Ballet J.J., Favennec L., Stachulski A.V., Rossignol J.F. Evaluation of new thiazolide/thiadiazolide derivatives reveals nitro group-independent efficacy against in vitro development of Cryptosporidium parvum. Antimicrob. Agents Chemother. 2010, 54:1315-1318.
51. Giacometti A., Cirioni O., Barchiesi F., Scalise G. Anticryptosporidial activity of ranalexin, lasalocid and azithromycin alone and in combination in cell lines. J. Antimicrob. Chemother. 2000, 45:375-377.
52. Giadinis N.D., Panousis N.K., Papadopoulos E., Antoniadou-Sotiriadou K., Karatzias H. The effects of halofuginone in cases of cryptosporidiosis in newborn lambs and kids in Greece. Proceedings of the 10th Greek Veterinary Congress 2006, 195-196. Hellenic Veterinary Medical Society, Athens.
53. Giadinis N.D., Papadopoulos E., Lafic S.Q., Panousis N.K., Papazahariadoub M., Karatzias H. Efficacy of halofuginone lactate for the treatment and prevention of cryptosporidiosis in goat kids: an extensive field trial. Small Rumin. Res. 2008, 76:195-200.
54. Gillespie T.R., Greiner E.C., Chapman C.A. Gastrointestinal parasites of the colobus monkeys of Uganda. J. Parasitol. 2005, 91:569-573.
55. Gookin J.L., Riviere J.E., Gilger B.C., Papich M.G. Acute renal failure in four cats treated with paromomycin. J. Am. Vet. Med. Assoc. 1999, 215:1821-1823.
56. Gookin J.L., Levy M.G., Law J.M., Papich M.G., Poore M.F., Breitschwerdt E.B. Experimental infection of cats with Tritrichomonas foetus. Am. J. Vet. Res. 2001, 62:1690-1697.
57. Gorham S.L., Mallinson E.T., Synder D.B., Odor E.M. Cryptosporidia in the bursa of Fabricius-a correlation with mortality rates in broiler chickens. Avian Pathol. 1987, 16:205-211.
58. Gracenea M., Gómeza M.S., Torresa J., Carnéa E., Fernández-Morán J. Transmission dynamics of Cryptosporidium in primates and herbivores at the Barcelona zoo: a long-term study. Vet. Parasitol. 2002, 104:19-26.
59. Graczyk Z., Chomicz L., Kozłowska M., Kazimierczuk Z., Graczyk T.K. Novel and promising compounds to treat Cryptosporidium parvum infections. Parasitol. Res. 2011, 10.1007/s00436-011-2290-y.
60. Grinberg A., Markovics A., Galindez J., Lopez-Villalobos N., Kosak A., Tranquillo V.M. Controlling the onset of natural cryptosporidiosis in calves with paromomycin sulphate. Vet. Rec. 2002, 151:606-608.
61. Hemphill A., Mueller J., Esposito M. Nitazoxanide, a broad-spectrum thiazolide anti-infective agent for the treatment of gastrointestinal infections. Expert Opin. Pharmacother. 2006, 7:953-964.
62. Hoblet K.H., Charles T.P., Howard R.R. Evaluation of lasalocidand decoquinate against coccidiosis resulting from natural exposure in weaned dairy calves. Am. J. Vet. Res. 1989, 50:1060-1063.
63. Hoffman K.A., Sandoval S.I. Cryptosporidiosis. Vet. Technol. 1989, 10:124.
64. Holmberg S.D., Moorman A.C., Von Bargen J.C., Palella F.J., Loveless M.O., Ward D.J., Navin T.R. Possible effectiveness of clarithromycin and rifabutin for cryptosporidiosis chemoprophylaxis in HIV disease. HIV out patient study. J. Am. Vet. Med. Assoc. 1998, 279:384-386.
65. Huang K., Yang S. Inhibitory effect of selenium on Cryptosporidium parvum infection in vitro and in vivo. Biol. Trace Elem. Res. 2002, 90:261-272.
66. Hunt E., Fu Q., Armstrong M.U., Rennix D.K., Webster D.W., Galanko J.A., Chen W., Weaver E.M., Argenzio R.A., Rhoads J.M. Oral bovine serum concentrate improves cryptosporidial enteritis in calves. Pediatr. Res. 2002, 51:370-376.
67. Jenkins M., Trout J.M., Higgins J., Dorsch M., Veal D., Fayer R. Comparison of tests for viable and infectious Cryptosporidium parvum oocysts. Parasitol. Res. 2003, 89:1-5.
68. Jarvie B.D., Trotz-Williams L.A., McKnight D.R., Leslie K.E., Wallace M.M., Todd C.G., Scharpe P.H., Peregrine A.S. Effect of halofuginone lactate on the occurrence of Cryptosporidium parvum and growth of neonatal dairy calves. J. Dairy Sci. 2005, 88:1801-1806.
69. Joachim A., Krull T., Schwarzkopf J., Daugschies A. Prevalence and control of bovine cryptosporidiosis in German dairy herds. Vet. Parasitol. 2003, 112:277-288.
70. Johnson E.H., Windsor J.J., Muirhead D.E., King G.J., Al-Busaidy R. Confirmation of the prophylactic value of paromomycin in a natural outbreak of caprine cryptosporidiosis. Vet. Res. Commun. 2000, 24:63-67.
71. Karanis P., Kourenti C., Smith H. Waterborne transmission of protozoan parasites: a worldwide review of outbreaks and lessons learnt. J. Water Health 2007, 5:1-38.
72. Klein P. Preventive and therapeutic efficacy of halofuginone-lactate against Cryptosporidium parvum in spontaneously infected calves: a centralised, randomised, double-blind, placebo-controlled study. Vet. J. 2007, 177:429-431.
73. Klein P., Cirioni O., Giacometti A., Scalise G. In vitro and in vivo activity of aurintricarboxylic acid preparations against Cryptosporidium parvum. J. Antimicrob. Chemother. 2008, 62:1101-1104.
74. Lallemand M., Villeneuve A., Belda J., Dubreuil P. Field study of the efficacy of halofuginone and decoquinate in the treatment of cryptosporidiosis in veal calves. Vet. Rec. 2006, 159:672-676.
75. Lappin M.R., Dowers K., Edsell D., Taton-Allen G., Jheney J. Cryptosporidiosis and inflammatory bowel disease in a cat. Feline Pract. 1997, 25:10-13.
76. Lefay D., Naciri M., Poirier P., Chermette R. Efficacy of halofuginone lactate in the prevention of cryptosporidiosis in suckling calves. Vet. Rec. 2001, 148:108-112.
77. Leoni F., Amar C., Nichols G., Pedraza-Diaz S., McLauchlin J. Genetic analysis of Cryptosporiidum from 2414 humans with diarrhoea in England between 1985 and 2000. J. Med. Microbiol. 2006, 55:703-707.
78. Li X., Brasseur P., Agnamey P., Lemeteil D., Favennec L., Ballet J.J., Rossignol J.F. Long-lasting anticryptosporidial activity of nitazoxanide in an immunosuppressed rat model. Folia Parasitol. (Praha) 2003, 50:19-22.
79. Lindsay D.S., Blagburn B.L., Sunderman C.A., Ernest J.A. Chemoprophylaxis of cryptosporidiosis in chickens using halofuginone, salinomycin, lasalocid or monensin. Am. J. Vet. Res. 1987, 48:354-355.
80. Lindsay D.S., Woods K.M., Upton S.J., Blagburn B.L. Activity of decoquinate against Cryptoporidium parvum in cell cultures and neonatal mice. Vet. Parasitol. 2000, 89:307-311.
81. MacDonald L.M., Sargent K., Armson A., Thompson R.C., Reynoldson J.A. The development of a real-time quantitative-PCR method for characterisation of a Cryptosporidium parvum in vitro culturing system and assessment of drug efficacy. Mol. Biochem. Parasit. 2002, 121:279-282.
82. Mahdi N.K., Ali N.H. Cryptosporidiosis among animal handlers and their livestock in Basrah, Iraq. East Afr. Med. J. 2002, 79:550-553.
83. Mancassola R., Reperant J.M., Naciri M., Chartier C. Chemoprophylaxis of Cryptosporidium parvum infection with paromomycin in kids and immunological study. Antimicrob. Agents Chemother. 1995, 39:75-78.
84. Mancassola R., Richard A., Naciri M. Evaluation of decoquinate to treat experimental cryptosporidiosis in kids. Vet. Parasitol. 1997, 69:31-37.
85. Marshall R.J., Flanigan T.P. Paromomycin inhibits C. infection of a human enterocyte cell line. J. Infect. Dis. 1992, 165:772-774.
86. McDonald V., Stables R., Warhurst D.C., Barer M.R., Blewett D.A., Chapman H.D., Connolly G.M., Chiodini P.L., McAdam K.P.W.J. In vitro cultivation of Cryptosporidium parvum and screening for anticryptosporidial drugs. Antimicrob. Agents Chemother. 1990, 34:1498-1500.
87. McKerrow J.H., Rosental P.J., Swenerton R., Doyle P. Development of protease inhibitors for protozoan infections. Curr. Opin. Infect. Dis. 2008, 21:668-672.
88. McLauchlin J., Amar C., Pedraza-Diaz S., Nichols G.L. Molecular epidemiological analysis of Cryptosproidium spp. In the United Kingdom: results of genotyping Cryptosporidium spp. in 1,705 fecal samples from humans and 105 fecal samples from livestock animals. J. Clin. Microbiol. 2000, 38:3984-3990.
89. Miller W.A., Lewis D.J., Pereira M.D., Lennox M., Conrad P.A., Tate K.W., Atwill E.R. Farm factors associated with reducing Cryptosporidium loading in storm runoff from dairies. J. Environ. Qual. 2008, 37:1875-1882.
90. Mohandas K., Sehgal R., Sud A., Malla N. Prevalence of intestinal parasitic pathogens in HIV-seropositive individuals in Northern India. Jpn. J. Infect. Dis. 2002, 55:83-84.
91. Moon H.W., Schwartz A., Welch M.J., McCann P.P., Runnels P.L. Experimental fecal transmission of human cryptosporidia to pigs and attempted treatment with an ornithine decarboxylase inhibitor. Vet. Pathol. 1982, 19:700-707.
92. Moore D.A., Atwill E.R., Kirk J.H., Brahmbhatt D., Herrera Alonso L., Hou L., Singer M.D., Miller T.D. Prophylactic use of decoquinate for infections with Cryptosporidium parvum in experimentally challenged neonatal calves. J. Am. Vet. Med. Assoc. 2003, 223:839-845.
93. Müller J., Wastling J., Sanderson S., Müller N., Hemphill A. A novel nitroreductase, GlNR1, interacts with nitazoxanide and other thiazolides. Antimicrob. Agents Chemother. 2007, 51:1979-1986.
94. Naciri M., Yvore P. Efficiency of halofuginone lactate in the treatment of experimental cryptosporidiosis in lambs. Rec. Med. Vet. 1989, 165:823-826.
95. Naciri M., Mancassola R., Yvore P. The effect of halofuginone lactate on experimental Cryptosporidium parvum infections in calves. Vet. Parasitol. 1993, 45:199-207.
96. Naciri M., Mancassola R., Répérant J.M., Canivez O., Quinque B., Yvoré P. Treatment of experimental ovine cryptosporidiosis with ovine or bovine hyperimmune colostrum. Vet. Parasitol. 1994, 53:173-190.
97. Naciri N., Bareille S., Fournier R., Holland W.G. Use of halofuginone in the control of Cryptosporidium parvum infections in sheep. Proceedings of the 6th International Sheep Veterinary Congress 2005, 257-258. G.C. Fthenakis, Q.A. McKellar (Eds.).
98. Naciri M., Mancassola R., Fort G., Danneels B., Verhaeghe J. Efficacy of amine-based disinfectant KENO™COX on the infectivity of Cryptosporidium parvum oocysts. Vet. Parasitol. 2011, 179:43-49.
99. Naguleswaran A., Alaeddine F., Guionaud C., Vonlaufen N., Sonda S., Jenoe P., Mevissen M., Hemphill A. Neospora caninum protein disulfide isomerase is involved in tachyzoite-host cell interaction. Int. J. Parasitol. 2005, 35:1459-1472.
100. Najdrowski M., Heckeroth A.R., Wackwitz C., Gawlowska S., Mackenstedt U., Kliemt D., Daugschies A. Development and validation of a cell culture based assay for in vitro assessment of anticryptosporidial compounds. Parasitol. Res. 2007, 101:161-167.
101. Nichols, G., Chalmers, R., Lake, I., Sopwith, W., Regan, M., Hunter, P., Grenfell, P., Harrison, F., Lane, C., 2006. Cryptosporidiosis: a report on the surveillance and epidemiology of Cryptosporidium infection in England and Wales. In: Drinking Water Directorate Contract Number DWI 70/2/201, pp. 1-142.
102. Nord J., Ma P., DiJohn D., Tzipori S., Tacket C.O. Treatment with bovine hyperimmune colostrum of cryptosporidial diarrhea in AIDS patients. AIDS 1990, 4:581-584.
103. Nydam D.V., Lindergard G., Santucci F., Schaaf S.L., Wade S.E., Mohammed H.O. Risk of infection with Cryptosporidium parvum and Cryptosporidium hominis in dairy cattle in the New York City watershed. Am. J. Vet. Res. 2005, 66:413-417.
104. O'Donoghue P.J. Cryptosporidium and cryptosporidiosis in man and mammals. Int. J. Parasitol. 1995, 25:139-195.
105. Ollivett T.L., Nydam D.V., Bowman D.D., Zambriski J.A., Bellosa M.L., Linden T.C., Divers T.J. Effect of nitazoxanide on cryptosporidiosis in experimentally infected neonatal dairy calves. J. Dairy Sci. 2008, 92:1643-1648.
106. ®) in field conditions. Vet. Parasitol. 2011, 180:354-357.
107. Peeters J.E., Villacorta I., Naciri M., Vanopdenbosch E. Specific serum and local antibody responses against Cryptoporidium parvum during medication of calves with halofuginone lactate. Infect. Immun. 1993, 61:4440-4445.
108. Perrucci S., Fichi G., Buggiani C., Rossi G., Flamini G. Efficacy of mangiferin against Cryptosporidium parvum in a neonatal mouse model. Parasitol. Res. 2006, 99:184-188.
109. Redman D.R., Fox J.E. The effect of varying levels of Deccox on experimental Cryptosporidia infections in Holstein bull calves. Proceedings. 26th Annu. Conv. Am. Assoc. Bov. Pract. 1993, 157-159.
110. Rehg J.E. Activity of azithromycin against cryptosporidia in immunosuppressed rats. J. Infect. Dis. 1991, 163:1293-1296.
111. Rehg J.E. The activity of halofuginone in immunosuppressed rats infected with Cryptosporidium parvum. J. Antimicrob. Chemother. 1995, 35:391-397.
112. Robertson L.J. Giardia and Cryptosporidium infections in sheep and goats: a review of the potential for transmission to humans via environmental contamination. Epidemiol. Infect. 2009, 137:913-921.
113. Robinson G., Elwin K., Chalmers R.M. Unusual Cryptosporidium genotypes in human cases of diarrhea. Emerg. Infect. Dis. 2008, 14:1800-1802.
114. Rochelle P.A., Marshall M.M., Mead J.R., Johnson A.M., Korich D.G., Rosen J.S., De L.R. Comparison of in vitro cell culture and a mouse assay for measuring infectivity of Cryptosporidium parvum. Appl. Environ. Microbiol. 2002, 68:3809-3817.
115. Rossignol J.F., Hidalgo H., Feregrino M., Higuera F., Gomez W.H., Romero J.L., Padierna J., Geyne A., Ayers M.S. A double-blind placebo-controlled study of nitazoxanide in the treatment of cryptosporidial diarrhoea in AIDS patients in Mexico. Trans. R. Soc. Trop. Med. Hyg. 1998, 92:663-666.
116. Rossignol J.F., Ayoub A., Ayers M.S. Treatment of diarrhea caused by Cryptosporidium parvum: a prospective randomized, double-blind, placebo-controlled study of Nitazoxanide. J. Infect. Dis. 2001, 184:103-106.
117. Rueda C., Fenoy S., Simon F., del A.C. Bobel-24 activity against Cryptosporidium parvum in cell culture and in a SCID mouse model. Antimicrob. Agents Chemother. 2008, 52:1150-1152.
118. Saini P.K., Ransom G., McNamara A.M. Emerging public health concerns regarding cryptosporidiosis. J. Am. Vet. Med. Assoc. 2000, 217:658-663.
119. Sayers G.M., Dillon M.C., Connolly E., Thornton L., Hyland E., Loughman E., O'Mahony M.A., Butler K.M. Cryptosporidiosis in children who visited an open farm. Commun. Dis. Rep. 1996, 6:R140-R143.
120. Schaffzin J.K., Keithly J., Johnson G. Large outbreak of cryptosporidiosis associated with a recreational water spraypark New York, 2005. Proceedings of the 55th Annual Conference of the Epidemic Intelligence Service. US Department of Health and Human Services 2006.
121. Schnyder M., Kohler L., Hemphill A., Deplazes P. Prophylactic and therapeutic efficacy of nitazoxanide against Cryptosporidium parvum in experimentally challenged neonatal calves. Vet. Parasitol. 2009, 160:149-154.
122. Scorza A.V., Lappin M.R. An update in three important protozoan parasitic infections in cats: cryptosporidiosis, giardiasis, and tritrichomoniasis. Vet. Med. 2006, 18-32(Suppl.).
123. Scorza A.V., Lappin M.R. Co-infection of Cryptosporidium and Giardia in naturally infected cats, in Diagnosis and Treatment of Cryptosporidiosis and Giardiasis in Cats and Dogs in the United States 2007, Clinical Sciences, Colorado State University, Fort Collins, CO.
124. Shahiduzzaman M., Dyachenko V., Obwaller A., Unglaube S., Daugschies A. Combination of cell culture and quantitative PCR for screening of drugs against Cryptosporidium parvum. Vet. Parasitol. 2009, 162:271-277.
125. Shahiduzzaman M., Dyachenko V., Khalafalla R.E., Desouky A.Y., Daugschies A. Effects of curcumin on Cryptosporidium parvum in vitro. Parasitol. Res. 2009, 105:1155-1161.
126. Shahiduzzaman M., Dyachenko V., Keidel J., Schmäschke R., Daugschies A. Combination of cell culture and quantitative PCR (cc-qPCR) to assess disinfectants efficacy on Cryptosporidium oocysts under standardized conditions. Vet. Parasitol. 2010, 167:43-49.
127. Shin G.A., Linden K.G., Arrowood M.J., Sobsey M.D. Low-pressure UV inactivation and DNA repair potential of Cryptosporidium parvum oocysts. Appl. Environ. Microbiol. 2001, 67:3029-3032.
128. Simon D.M., Cello J.P., Valenzuela J., Levy R., Dickerson G., Goodgame R., Brown M., Lyche K., Fessel W.J., Grendell J., Wilcox C.M., Afdhal N., Fogel R., Reevesdarby V., Stern J., Smith O., Graziano F., Pleakow D., Flanigan T. Multicenter trial of octreotide in patients with refractory acquired immunodeficiency syndrome-associated diarrhea. Gastroenterology 1995, 108:1753-1760.
129. Slifko T.R., Friedman D., Rose J.B., Jakubowski W. An in vitro method for detecting infectious Cryptosporidium oocysts with cell culture. Appl. Environ. Microbiol. 1997, 63:3669-3675.
130. Sréter T., Széll Z., Varga I. Anticryptosporidial prophylactic efficacy of enrofloxacin and paromomycin in chickens. J. Parasitol. 2002, 88:209-211.
131. Sveriges Radio, 2010, http://www.sverigesradio.se/.
132. Stachulski A.V., Berry N.G., Lilian Low A.C., Moores S.L., Row E., Warhurst D.C., Adagu I.S., Rossignol J.F. Identification of isoflavone derivatives as effective anticryptosporidial agents in vitro and in vivo. J. Med. Chem. 2006, 49:1450-1454.
133. Thamsborg S.M., Jørgensen R.J., Henriksen S.A. Cryptosporidiosis in kids of dairy goats. Vet. Rec. 1990, 127:627-628.
134. Theodos C.M., Griffiths J.K., D'Onfro J., Fairfield A., Tzipori S. Efficacy of nitazoxanide against Cryptosporidium parvum in cell culture and in animal models. Antimicrob. Agents Chemother. 1998, 42:1959-1965.
135. Trotz-Williams L.A., Jarvie B.D., Peregrine A.S., Duffield T.F., Leslie K.E. Efficacy of halofuginone lactate in the prevention of cryptosporidiosis in dairy calves. Vet. Rec. 2011, 168:509.
136. Tzipori S.R., Campbell I., Angus K.W. The therapeutic effect of 16 antimicrobiological agents on infection in mice. Aust. J. Exp. Med. Sci. 1982, 60:187.
137. Tzipori S., Rand W., Griffiths J., Widmer G., Crabb J. Evaluation of an animal model system for cryptosporidiosis: therapeutic efficacy of paromomycin and hyperimmune bovine colostrum-immunoglobulin. Clin. Diagn. Lab. Immunol. 1994, 1:450-463.
138. van Zeeland Y.R., Schoemaker N.J., Kik M.J., van der Giessend J.W. Upper respiratory tract infection caused by Cryptosporidium baileyi in three mixed-bred falcons (Falco rusticolus×Falco cherrug). Avian Dis. 2008, 52:357-363.
139. Verdon R., Polianski J., Gaudebout C., Marche C., Garry L., Carbon C., Pocidalo J.J. Evaluation of high-dose regimen of paromomycin against cryptosporidiosis in the dexamethasone-treated rat model. Antimicrob. Agents Chemother. 1995, 39:2155-2157.
140. Viel H., Rocques H., Martin J., Chartier C. Efficacy of nitazoxanide against experimental cryptosporidiosis in goat neonates. Proceedings of the 21st International Conference of the W. A. A. V. P 2007, 490.
141. Villacorta I., Peeters J.E., Vanopdenbosch E., Ares-Mazás E., Theys H. Efficacy of halofuginone lactate against Cryptosporidium parvum in calves. Antimicrob. Agents Chemother. 1991, 35:283-287.
142. Viu M., Quílez J., Sánchez-Acedo C., del Cacho E., López-Bernad F. Field trial on the therapeutic efficacy of paromomycin on natural Cryptosporidium parvum infections in lambs. Vet. Parasitol. 2000, 90:163-170.
143. Watarai S., Tana, Koiwa M. Feeding activated charcoal from bark containing wood vinegar liquid (Nekka-Rich) is effective as treatment for cryptosporidiosis in calves. J. Dairy Sci. 2008, 91:1458-1463.
144. Woods K.M., Nesterenko M.V., Upton S.J. Development of a microtitre ELISA to quantify development of Cryptosporidium parvum in vitro. FEMS Microbiol. Lett. 1995, 128:89-94.
145. Xiao L., Ryan U.M., Graczyk T.K., Limor J., Li L., Kombert M., Junge R., Sulaiman I.M., Zhou L., Arrowood M.J., Koudela B., Modry D., Lal A.A. Genetic diversity of Cryptosporidium sp. in captive reptiles. Appl. Environ. Microbiol. 2004, 70:891-899.
146. Xiao L., Fayer R., Ryan U., Upton S.J. Cryptosporidium taxonomy: recent advances and implications for public health. Clin. Microbiol. 2004, 17:72-97.